|
1 Indications And Usage Nerlynx Is A Kinase Inhibitor Indicated: As A Single Agent, For The Extended Adjuvant Treatment Of Adult Patients With Early Stage Her2-Positive Breast Cancer, To Follow Adjuvant Trastuzumab-Based Therapy. ( 1.1 ) In Combination With Capecitabine, For The Treatment Of Adult Patients With Advanced Or Metastatic Her2-Positive Breast Cancer Who Have Received Two Or More Prior Anti-Her2 Based Regimens In The Metastatic Setting. ( 1.2 ) 1.1 Extended Adjuvant Treatment Of Early-Stage Breast Cancer Nerlynx As A Single Agent Is Indicated For The Extended Adjuvant Treatment Of Adult Patients With Early-Stage Human Epidermal Growth Factor Receptor 2 (Her2)-Positive Breast Cancer, To Follow Adjuvant Trastuzumab Based Therapy [See Clinical Studies ( 14.1 )] . 1.2 Advanced Or Metastatic Breast Cancer Nerlynx In Combination With Capecitabine Is Indicated For The Treatment Of Adult Patients With Advanced Or Metastatic Her2-Positive Breast Cancer Who Have Received Two Or More Prior Anti-Her2 Based Regimens In The Metastatic Setting . Nerlynx In Combination With Capecitabine Is Indicated For The Treatment Of Adult Patients With Advanced Or Metastatic Her2-Positive Breast Cancer Who Have Received Two Or More Prior Anti-Her2 Based Regimens In The Metastatic Setting [See Clinical Studies ( 14.2 )] .
|